The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hirokazu Shoji
No Relationships to Disclose
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Kyowa Hakko Kirin; Lilly
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Nozomu Machida
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - MSD
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Senju Pharmaceutical
 
Kazunori Aoki
No Relationships to Disclose
 
Kazufumi Honda
No Relationships to Disclose
 
Takahiro Miyamoto
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)